Product Information
PYRAZINAMIDE 500 MG TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $1.3081 per EA under NDC 00054081221. Its NADAC has been published 96 times since Dec 4, 2024.
FDA first approved this application on Jun 30, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054081221
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PYRAZINAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA081319FDA Approved
6/30/1992
TE Code
AB
On Market Since
8/30/2024
Pharmacological Classes
Price Statistics
The NADAC for PYRAZINAMIDE 500 MG TABLET has been published 96 times since Dec 4, 2024, and over the history we have for it it has declined 46.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3081 per EA |
|---|---|
| All-time high | $2.5260 (Aug 13, 2025) |
| All-time low | $1.3081 (Sep 23, 2026) |
| 52-week high | $2.3801 |
| 52-week low | $1.3081 |
| Median price | $2.2953 |
| Average price | $2.0662 |
| Largest weekly change | -9.0% (Jan 21, 2026) |
| Weeks tracked | 96 |
| Tracking since | Dec 4, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pyrazinamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimycobacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PYRAZINAMIDE 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PYRAZINAMIDE 500 MG TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $1.3081 per EA (NDC 00054081221), effective Sep 30, 2026.
How has the price of PYRAZINAMIDE 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for PYRAZINAMIDE 500 MG TABLET has declined 46.6%. It has been tracked across 96 weekly CMS publications since Dec 4, 2024.
What are the highest and lowest recorded NADAC prices for PYRAZINAMIDE 500 MG TABLET?
Since Dec 4, 2024, the NADAC for PYRAZINAMIDE 500 MG TABLET has ranged from a low of $1.3081 (Sep 23, 2026) to a high of $2.5260 (Aug 13, 2025), with a median of $2.2953 per EA.
Are there cheaper alternatives to PYRAZINAMIDE 500 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PYRAZINAMIDE 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PYRAZINAMIDE 500 MG TABLET?
PYRAZINAMIDE 500 MG TABLET (NDC 00054081221) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.